All articles tagged with #statins
McMaster University researchers have shown that statins can disrupt muscle cell energy production, triggering immune signaling that leads to inflammation and muscle damage. Blocking this immune response reduced damage, suggesting side effects may be separable from cholesterol-lowering benefits and could guide future therapies to improve statin tolerability.
LDL cholesterol is the “bad” type that can quietly build arterial plaque and raise the risk of heart attack or stroke. Testing is essential since many people don’t know their level; optimal LDL is 100 mg/dL or lower. Genetics and aging influence levels, but lifestyle matters too: limit saturated fats, eat a plant-forward, high-fiber diet, avoid tobacco, exercise at least 150 minutes per week, and manage stress and sleep. If lifestyle changes aren’t enough or you have high risk, a doctor may prescribe statins or other medications that can markedly lower LDL.
A Northwestern Medicine study in JAMA finds that apoB testing, which counts harmful cholesterol particles, better guides the decision to intensify cholesterol-lowering therapy than LDL or non-HDL testing, potentially preventing more heart attacks and strokes while remaining cost-effective for U.S. healthcare, based on a computer model comparing three strategies in 250,000 adults.
Statins are cholesterol-lowering medicines prescribed after a GP-based cardiovascular risk assessment; they reduce LDL (and sometimes triglycerides), with atorvastatin being the most commonly prescribed type, and are usually taken nightly with regular follow-up blood tests. They work best alongside a healthy lifestyle, and stopping them should only be done under medical guidance since cholesterol can rise again. While many people report side effects, a Lancet study found no significant increase in most adverse effects; certain individuals (pregnant/nursing, liver or kidney problems, previous reactions) may not be eligible. Grapefruit should be avoided because it can affect effectiveness.
A Lancet analysis of almost 1 million adults across countries shows that older adults with obesity have cholesterol levels and systolic blood pressure similar to or better than those with a healthy weight, largely due to widespread use of statins and antihypertensive drugs. Younger adults with obesity still exhibit higher risk, but overall these medications are narrowing cardiometabolic differences between groups. The findings highlight a public health success in treating risk factors, while obesity remains linked to other health problems and the need for ongoing weight management and early intervention.
A Lancet analysis of 1 million adults across 110 datasets (1990–2024) finds that people aged 40–79 with overweight or obesity have seen sharper improvements in blood pressure and unhealthy cholesterol than normal-weight peers, leading to risk-factor levels by ages 60–70 that rival or exceed those of normal BMI. Younger adults under 40 do not show the same convergence. The changes are likely driven by wider use of affordable antihypertensives and statins, but the study is observational and obesity remains linked to other health risks; obesity drugs were not included, underscoring the need for prevention in youth.
A Lancet Digital Health study using health records from nearly 6 million UK adults shows the 10-year risk of serious statin-related muscle disorders (myopathy, myalgia, rhabdomyolysis) is about 0.04%, far lower than prior estimates. Most reported muscle symptoms are mild or due to other causes, and risk is influenced by factors like kidney disease, other medications, and vitamin D deficiency. Clinicians can personalize risk with new tools; statins remain highly beneficial for lowering LDL and reducing heart attack or stroke risk, and patients should discuss risks with their doctor rather than fear rare side effects.
A health feature examines how social media myths about statins skew public perception, while evidence shows statins safely lower LDL and reduce heart attack and stroke risk. It notes online misinformation and under-treatment of women, and highlights the latest AHA/ACC guidelines calling for earlier cholesterol testing (starting around age 30) and shared decision-making. New tests like lipoprotein(a) and apoB, plus possible coronary calcium scans, help tailor treatment. While lifestyle changes remain important, statins can be lifesaving for many patients, with doctors adjusting therapy to individual risk.
The portfolio diet combines four LDL-lowering components—plant protein (soy), plant sterols, tree nuts, and soluble fiber—into a daily plan and may reduce LDL cholesterol by up to about 29–30%, in some cases rivaling low-dose statins. Key targets include 35 g/day of plant protein, 2 g/day of plant sterols, 42 g/day of tree nuts, and 18 g/day of soluble fiber, with psyllium husk and fortified foods helping meet goals. While promising, statins have additional benefits beyond LDL reduction, and you should follow a clinician’s advice if prescribed.
The American College of Cardiology and the American Heart Association issued new cholesterol guidelines: start screening earlier, add a one-time Lp(a) test, use a smarter PREVENT risk calculator, lower LDL targets (below 100 for healthy, under 70 for medium risk, under 55 for high risk), and expand treatment options with newer meds alongside lifestyle changes. The piece also links health stewardship to Jewish law, outlining six mitzvot that emphasize protecting life and well-being and urging individual doctor-guided plans.
A global study of 460 million lipid tests across 17 countries finds South Korea has the lowest LDL ('bad') cholesterol, while Austria and Germany have the highest, with Japan, Australia and Switzerland just below high levels; Turkey and the United States also show below-average levels. Diets rich in fermented foods and legumes and low saturated fat may explain Korea's low levels, while higher animal fats and dairy contribute to higher levels elsewhere; genetics (including familial hypercholesterolemia) also plays a role. Over 1980–2018, cholesterol declined in high-income Western nations due to diet changes and statin use, while many low- and middle-income countries saw increases, especially in Asia; men tend to have higher cholesterol than women.
The ACC/AHA issued major updates to cholesterol guidelines—the first since 2018—emphasizing earlier detection (including possible screening starting at age 9 for those with a family history), more aggressive, personalized statin therapy, and a renewed focus on lifestyle changes; saturated fats are highlighted as the primary dietary driver of blood cholesterol, not dietary cholesterol, and a new validated tool helps clinicians tailor treatment.
Remnant cholesterol, carried by large lipoprotein particles and rich in triglycerides, may drive heart disease more than LDL; it’s rarely measured, and while statins mostly lower LDL, newer drugs plus diet and weight loss can significantly reduce remnant cholesterol and cardiovascular risk.
A DNA-based treatment using polypurine hairpins to silence PCSK9 lowers LDL cholesterol and boosts LDL receptors. In liver cells HpE9/HpE12 reduced PCSK9 RNA by up to 74% and protein by up to 87%; in transgenic mice a single injection cut PCSK9 by ~50% and cholesterol by ~47% within days, potentially offering a statin-free alternative with fewer side effects.
Doctors lowered the LDL cholesterol targets and tied them to an individual’s overall cardiovascular risk, enabling earlier, risk-driven prevention. The guidance uses the PREVENT calculator to decide when lifestyle changes suffice versus when medications should begin, with statins remaining first-line and quicker escalation to ezetimibe or injections if needed. The update also recommends testing lipoprotein(a) and apolipoprotein B, considers targeted imaging in uncertain cases, and calls for earlier screening (adults at 19; kids around 9–11) to detect inherited hypercholesterolemia and start prevention before emergencies.